+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiovascular and Soft Tissue Repair Patches Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 117 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5026071
UP TO OFF until Sep 30th 2022

The Cardiovascular and Soft Tissue Repair Patches Market is expected to register a CAGR of 8% during the forecast period. This is attributing to technological advancements, increasing prevalence of congenital heart diseases, increasing R&D expenditure. In addition, the rising prevalence of atrial and ventricular septal in hearth birth defects and growing inclination towards minimally invasive procedures also result in high adoption of the patches and trigger the growth of the market. Moreover, increase in the prevalence of congenital diaphragmatic hernias, an inguinal hernia is also promoting the growth pf the market as these patches are used in the treatment of these disorders by tissue repairing procedures. As per the National Institute of Diabetes and Digestive and Kidney Diseases, an inguinal hernia is a common disorder around the globe and representing at least 27 percent of men and 3 percent of women at some point in their lives. Furthermore, increasing collaboration between manufacturers and research organizations, government initiatives associated with cardiac treatments, and the development of novel technologies are few more factors driving the growth of cardiovascular and soft tissue repair patches market.

Key Market Trends

Soft Tissue Repair in Cardiac and Soft Tissue Repair Patches is Estimated to Witness a Healthy Growth in Future.

Soft tissue repair is estimated to witness healthy growth in the future attributed to the increasing prevalence of various types of hernias. A hernia is a disorder where an organ or any fatty tissue bulges out though an abnormal opening. Soft tissue repair patches help in diagnosing the hernia disorder. As per the report published by Santhini Elango in 2017, the incidence of hernia is rising at an alarming rate among the population over 50 years old in India and around 2% of the population are affected by hernia making it highly prevalent across the globe and drive the segment growth.

In addition, As per SWEDCON, the number of children with congenital heart diseases is increasing from the past year and thus leading to the adoption of these cardiovascular soft tissue repair patches for diagnosing and drive the overall market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Cardiovascular and Soft Tissue Repair Patches Market due to the rising prevalence of cardiac diseases, the presence of a large number of pharmaceutical companies, growing research and development expenditure, and increasing incidences of hernia disorders.

As per the report published in Annals of Laparoscopic and Endoscopic Surgery 2019, annually 350,000 abdominal wall hernia repairs are being performed in the United States. The United States owns the largest share of Cardiovascular and Soft Tissue Repair Patches Market in the North America region Furthermore, the presence of developed infrastructure and growing awareness regarding the availability of novel products are also expected to fuel the Cardiovascular and Soft Tissue Repair Patches Market in this region.

Competitive Landscape

The Cardiovascular and Soft Tissue Repair Patches Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Admedus, LeMaitre Vascular Inc., Baxter, Cryolife, Inc., CorMatrix, Inc, Abbott (St Jude Medical), B. Braun Melsungen AG, Terumo Medical Corporation, Integra LifeSciences Corporation, and Glycar SA Pty Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements
4.2.2 Increasing Prevalence of Congenital Heart Diseases
4.2.3 Increasing R&D Expenditure
4.3 Market Restraints
4.3.1 Regulatory Framework
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Raw Material
5.1.1 Biomaterial and Tissue Engineered Material
5.1.2 ePTFE
5.1.3 Others
5.2 By Application
5.2.1 Cardiac Repair
5.2.2 Soft Tissue Repair
5.2.3 Vascular Repair & Reconstruction
5.2.4 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Admedus
6.1.2 LeMaitre Vascular Inc.
6.1.3 Baxter
6.1.4 Cryolife, Inc.
6.1.5 CorMatrix, Inc
6.1.6 Abbott (St Jude Medical)
6.1.7 B. Braun Melsungen AG
6.1.8 Terumo Medical Corporation
6.1.9 Integra LifeSciences Corporation
6.1.10 Glycar SA Pty Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Admedus
  • LeMaitre Vascular Inc.
  • Baxter
  • Cryolife, Inc.
  • CorMatrix, Inc
  • Abbott (St Jude Medical)
  • B. Braun Melsungen AG
  • Terumo Medical Corporation
  • Integra LifeSciences Corporation
  • Glycar SA Pty Ltd.